Acta Virol. 2023;67(1):79-90. doi: 10.4149/av_2023_108.
Equine herpesvirus 1 (EHV1) infection is a global health problem in equines and the virus is responsible for abortions, respiratory disease and myeloencephalitis in horses. Disease management requires proper biosecurity and immunoprophylactic measures. Vaccines strengthening both arms of immunity are essential for proper control and there has been a continuous focus in this area for generation of better vaccines. Here we report construction of bacterial artificial chromosome (BAC) clone of EHV-1 strain Tohana for mutagenesis of the virus and generation of gE gene deletion mutant EHV1. The BAC clone was generated by inserting the mini-F plasmid replacing ORF71 of EHV1 and transforming into E. coli for generation of EHV1-BAC. The infectious virus was regenerated from EHV-1 BAC DNA in RK13 cells. To check utility of EHV1-BAC, we have generated mutant EHV1 by deleting the virulence-associated gE gene. The mutant virus (vToHΔgE) showed significantly reduced plaque size without affecting replication efficiency. Pathological evaluation of lesions in BALB/c mice infected with vToHΔgE revealed reduction in clinical signs and pathology in comparison to the wild-type virus. Generation of infectious BAC of EHV1 and its usage in construction of attenuated viruses shows potential of the technology for development of indigenous modified live vaccine for EHV1. Keywords: quine herpesvirus 1; bacterial artificial chromosome (BAC); mutation; glycoprotein E; vaccine.
马疱疹病毒 1 型(EHV1)感染是马属动物的全球性健康问题,该病毒可导致马流产、呼吸道疾病和脑脊髓炎。疾病管理需要采取适当的生物安全和免疫预防措施。为了进行有效的控制,必须使用能够增强两种免疫途径的疫苗,并且一直在该领域不断关注以生成更好的疫苗。在这里,我们报告了 Tohana 株 EHV-1 的细菌人工染色体(BAC)克隆的构建,用于病毒的诱变和 gE 基因缺失突变体 EHV1 的生成。BAC 克隆是通过插入 mini-F 质粒取代 EHV1 的 ORF71 并转化为大肠杆菌来生成 EHV1-BAC 而构建的。从 RK13 细胞中的 EHV-1 BAC DNA 中再生出感染性病毒。为了检查 EHV1-BAC 的实用性,我们通过删除与毒力相关的 gE 基因生成了突变体 EHV1。突变病毒(vToHΔgE)的蚀斑大小明显减小,而不影响复制效率。与野生型病毒相比,用 vToHΔgE 感染 BALB/c 小鼠后的病变的病理评估表明临床症状和病理学均有所减轻。EHV1 的传染性 BAC 的生成及其在减毒病毒构建中的使用表明,该技术有潜力用于开发本土改良活疫苗用于 EHV1。关键词:马疱疹病毒 1 型;细菌人工染色体(BAC);突变;糖蛋白 E;疫苗。